Zoetis Inc.

Zoetis Inc. held its 2026 Annual Meeting of Shareholders on May 20, 2026, where shareholders voted on five proposals. Prior to the meeting, Ms. Louise M. Parent retired from the Board of Directors. Shareholders elected twelve directors, approved the executive compensation program on an advisory basis, and decided to hold future advisory votes on executive compensation annually. Additionally, KPMG LLP was ratified as the independent auditor, while a shareholder proposal to permit action by written consent was not approved.

Zoetis Inc. announced that its Board of Directors has declared a dividend of $0.53 per share for the third quarter of 2026. This dividend is scheduled to be paid on September 1, 2026, to all shareholders of record as of the close of business on July 20, 2026.

Zoetis Inc. announced a definitive agreement to acquire Neogen Corporation's animal genomics business, expected to close in the second half of 2026. For the first quarter of 2026, the company reported revenue of $2.26 billion, a 2.9% increase from the recast prior year. Net income attributable to Zoetis Inc. was $601 million, with diluted earnings per share of $1.42, up from $1.34 in the recast prior year, primarily due to fewer outstanding shares. The company also incurred $22 million in restructuring charges.

Zoetis Inc. reported first-quarter 2026 revenue of $2.3 billion, a 3% increase year-over-year, with net income at $601 million and diluted EPS at $1.42. Adjusted net income rose 2% to $646 million, with adjusted diluted EPS up 9% to $1.53. The company faced a challenging operating environment with increased pet owner price sensitivity and intensified competition, leading to an 8% decline in U.S. segment revenue, while international revenue grew 17%. Zoetis revised its full-year 2026 revenue guidance to $9.680 - $9.960 billion and adjusted diluted EPS guidance to $6.85 - $7.00, while also announcing the acquisition of Neogen's animal genomics business.